Proacta S.A., a bioinformatics company listed on the NewConnect market, increased its estimated net sales revenue to PLN 4.7 million in the third quarter of 2025 — a 175% year-on-year increase. EBITDA reached nearly PLN 2.1 million, compared with just under PLN 0.1 million a year earlier, while net profit exceeded PLN 1.4 million, reversing a net loss of approximately PLN 0.5 million recorded in the same period last year. As a result, Proacta has once again delivered a significant improvement in its financial performance, driven by the execution of framework agreements with key partners and the active development of its IT and bioinformatics project portfolio.
“Quarter after quarter, we improve our financial results and steadily scale our operations. We have a secure backlog based on long-term framework agreements, and we are simultaneously working on further expanding our client base. Our personnel resources and technological capabilities allow us to diversify our activities — both in the healthcare sector and for commercial clients,”
said Maciej Grzywacki, Vice President of the Management Board of Proacta S.A.
Key Contracts Driving Growth
In Q3 2025, Proacta began implementing two major contracts:
- Bank Guarantee Fund (BFG) – PLN 17.5 million contract for the development and maintenance of a strategic IT system, with Proacta responsible for 98% of the project.
- Institute of Physiology and Pathology of Hearing (IFPS) – PLN 4.91 million contract to develop an AI-based system for analysing genetic and audiological data. The tool will support prediction of disease progression and enable personalised care for patients with hearing impairment.
Over the past several years, Proacta has built strong competencies in medical data analysis and predictive algorithm development — a key competitive advantage in its collaboration with medical and scientific institutions.
Rising Demand for Data-Driven Healthcare Solutions
“We see growing demand from both commercial and public-sector institutions, particularly in data-driven healthcare services. This sector now has greater financial resources, and the National Recovery Plan has introduced significant funding for new technologies in hospitals and medical facilities. Interest in our health-analysis solutions continues to rise. We also observe strong engagement from institutions implementing the government’s My Health programme. Our products fit perfectly into these initiatives, helping optimise processes and improve patient care.
Increasingly, our portfolio includes products undergoing certification, which will further strengthen our position in the medical technology segment,”
noted Paweł Ciesielka, President of the Management Board of Proacta S.A.
Strategic Partnership in the Polish Health Labs4Value Network
In August 2025, Proacta signed a cooperation agreement within the Polish Health Labs4Value Network (PSHL4V) alongside leading scientific and medical institutions, including the Medical University of Łódź and the Łódź University of Technology. The partnership, which becomes effective on 1 March 2026, aims to accelerate innovation in healthcare, support digital and telemedicine solutions, and jointly apply for research and implementation funding.
As a technological partner, Proacta will be responsible for developing and testing advanced IT solutions that will support treatment and diagnostic processes.
Source: ceo.com.pl / Proacta z kolejnym udanym kwartałem – wzrost przychodów o 175% i zysk netto na poziomie 1,4 mln zł
